Home » Stocks » GlaxoSmithKline

GlaxoSmithKline plc (GSK)

Stock Price: $36.53 USD -0.05 (-0.12%)
Updated Oct 19, 2020 10:13 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 90.90B
Revenue (ttm) 44.41B
Net Income (ttm) 4.65B
Shares Out 2.49B
EPS (ttm) 0.99
PE Ratio 36.89
Forward PE 12.22
Dividend $1.89
Dividend Yield 5.17%

Stock Quote

Trading Day Oct 19, 2020
Last Price $36.53
Previous Close $36.57
Change ($) -0.05
Change (%) -0.12%
Day's Open 36.62
Day's Range 36.52 - 36.77
Day's Volume 650,949
52-Week Range 31.43 - 48.25

More Stats

Market Cap 90.90B
Enterprise Value 124.75B
Earnings Date (est) Oct 28, 2020
Ex-Dividend Date Aug 13, 2020
Shares Outstanding 2.49B
Float 2.49B
EPS (basic) n/a
EPS (diluted) 0.99
FCF / Share 4.09
Dividend $1.89
Dividend Yield 5.17%
Earnings Yield 2.71%
FCF Yield 12.10%
Payout Ratio 82.50%
Shares Short 11.08M
Short Ratio 3.73
Short % of Float 0.45%
Beta 0.34
PE Ratio 36.89
Forward PE 12.22
P/FCF Ratio 8.26
PS Ratio 2.05
PB Ratio 5.19
Revenue 44.41B
Operating Income 9.16B
Net Income 4.65B
Free Cash Flow 11.00B
Net Cash -33.84B
Net Cash / Share -13.59
Gross Margin 64.85%
Operating Margin 20.62%
Profit Margin 13.80%
FCF Margin 24.77%
ROA 7.38%
ROE 63.64%
ROIC 17.40%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (23)

Buy 11
Overweight 1
Hold 8
Underweight 0
Sell 3

Analyst Consensus: Overweight

Price Target

(31.25% upside)
Current: $36.53
Target: 47.94
*Average 12-month USD price target from 18 stock analysts.

Financial Performance

Financial numbers in millions GBP.

Financial Overview

Revenue Growth9.52%2.1%8.24%16.58%3.99%-13.2%0.28%-3.49%-3.54%-
Gross Profit21,89120,58019,84418,59915,07015,68317,92018,50619,71420,494
Operating Income6,9615,4834,0872,59810,3223,5977,0287,3007,7343,783
Net Income4,6453,6231,5329128,4222,7565,4364,4995,2081,634
Shares Outstanding5,3795,3735,3685,3615,3555,3425,3985,0495,1965,191
Earnings Per Share1.851.460.620.373.451.132.211.802.040.64
EPS Growth27.02%135.16%66.67%-89.2%203.88%-48.69%22.51%-11.66%220.06%-
Dividend Per Share2.
Dividend Growth-5.43%5.17%-26%13.16%-7.7%10.09%-2.79%12.34%10.36%-
Operating Cash Flow9,5329,7478,2588,1064,6316,2848,4996,0487,7138,631
Capital Expenditures-1,170-1,176-1,264-1,445-1,308-1,149-1,142-983-823-922
Free Cash Flow8,3628,5716,9946,6613,3235,1357,3575,0656,8907,709
Cash & Equivalents4,7863,9583,9114,9865,9054,4075,6004,2655,8986,241
Total Debt30,50826,06417,08918,79016,63218,78418,24518,30214,90115,100
Net Cash / Debt-25,722-22,106-13,178-13,804-10,727-14,377-12,645-14,037-9,003-8,859
Book Value11,4053,781-68.001,1245,1144,2636,9975,8008,0328,887
Numbers in millions GBP, except per-share numbers.

Company Profile

Company Details

Full Name GlaxoSmithKline plc
Country United Kingdom
Employees 99,437
CEO Emma N. Walmsley

Stock Information

Ticker Symbol GSK
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NYSE: GSK


GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; CureVac; and research collaboration with Sengenics focusing on immunology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.